The startup develops therapeutic whole-cell cancer vaccines that utilize tumor-associated antigens to activate the patient's immune system for targeted cancer treatment. This approach enables oncologists to customize therapies based on individual patient conditions, enhancing treatment efficacy.
Funding
$15M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current cancer vaccines often have limited scope, are expensive to produce, and are difficult to integrate into routine clinical care, thus failing to reach their full potential in providing broad immune responses and impacting patient outcomes. Tumors are not uniform and can evade therapies as they evolve and adapt.
Solution
NEUVOGEN is developing off-the-shelf, therapeutic whole-cell cancer vaccines designed to deliver a broader immune response, reach more patients earlier in their care journey, and integrate into routine clinical settings. The vaccines utilize a proprietary activation technology to drive T cell responses against a wide and diverse set of tumor antigens, targeting the primary tumor, micro-metastases, and metastases by activating the patient’s own immune system. Engineered cell lines are selected using advanced bioinformatics and screening to reflect the complexity and diversity of each cancer type, then enhanced to express a broad range of cancer antigens. The resulting master vaccine cocktails are stable, scalable, and ready for clinical use, administered intradermally without patient-specific customization.
Target Audience
The primary target audience includes oncologists and healthcare providers seeking to enhance cancer treatment options with readily available, cost-effective vaccine therapies, as well as patients with solid tumor cancers across various stages of disease.
Features
- Off-the-shelf cancer vaccines designed for broad accessibility and simplified logistics
- Proprietary activation technology to stimulate a diverse T cell response against tumor antigens
- Engineered cell lines selected via bioinformatics to represent the heterogeneity of cancer
- Designed to target primary tumors, micro-metastases, and metastases
- Intradermal administration for ease of use in various clinical settings
- Scalable manufacturing process to lower the cost of goods